Feinberg principal investigators secured $650 million in research funding and awards during the 2021-22 fiscal year, which is a 6.5 percent increase over the previous year, and the largest amount in the school’s history.
The Robert H. Lurie Comprehensive Cancer Center of Northwestern University will begin scaling up its collection and use of data related to patient sex assigned at birth, gender identity, and sexual orientation with funding from the National Cancer Institute.
A new study has shown that energy release may be the molecular mechanism through which our internal clocks control energy balance, findings with implications from dieting to sleep loss.
Telmisartan, an angiotensin receptor blocker drug, did not improve walking performance in patients with lower extremity peripheral artery disease, according to a recent clinical trial published in JAMA.
Northwestern Medicine investigators have discovered that dopaminergic neurons in the substantia nigra utilize a specific ion channel to control energy production and meet bioenergetic need, according to a recent study.
Northwestern University Trustee Kimberly K. Querrey and the Louis Simpson Trust have made a new $100 million gift to the Feinberg School of Medicine to significantly expand the university’s biomedical research enterprise.
The Supreme Court ruling in Dobbs v. Jackson Women’s Health Organization has created confusion for many women seeking medical care when pregnant. Nevertheless, Feinberg investigators continue to pursue research that identifies important factors that impact maternal health.
Sara Becker, PhD, director of IPHAM’s Center for Dissemination and Implementation Science, and C Hendricks Brown, PhD, professor of Psychiatry and of Behavioral Sciences, are principal investigators on a new $15.8 million center grant funded by the National Institute on Drug Abuse.
Using machine learning, Northwestern scientists have demonstrated that the protein membrane CD81 interacts with CD44 in promoting tumor cell cluster formation and lung metastasis of triple negative breast cancer.
Targeting internal proteins instead of spike proteins may be a promising strategy for monoclonal antibody therapy to combat SARS-CoV-2, the virus that causes COVID-19.